3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihy dro3-methyl-5-oxo-4H-pyrazol-4-ylidene]hy drazino]-2'-hydroxy-[1,1'-biphenyl]-3-car boxylic acid bis-(monoethanolamine)

Details for Australian Patent Application No. 2003241587 (hide)

International Classifications

Event Publications

11 September 2003 Complete Application Filed

Priority application(s): 60/382,871 22.05.02 US

5 February 2004 Application Open to Public Inspection

Published as AU-B-2003241587

4 October 2007 Application Accepted

Published as AU-B-2003241587

31 January 2008 Standard Patent Sealed

19 August 2010 Alteration of Name

The name of the patentee has been altered to GlaxoSmithKline LLC

25 November 2010 Extension of Term of Standard Patents

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 16 Jul 2010 For the goods REVOLADE eltrombopag

23 December 2010 Extension of Term of Standard Patents

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 16 Jul 2010 For the goods REVOLADE eltrombopag Address for service in Australia: Davies Collison Cave 1 Nicholson Street Melbourne VIC 3000 Extensions of Term of Standard Patents Extension of Term of a Standard Patent relating to Pharmaceutical Substances

28 April 2011 Extension granted

GlaxoSmithKline LLC The earliest first regulatory approval date provided by the patentee 16 Jul 2010 For the goods REVOLADE eltrombopag Extension of Term of patent pursuant to Section 77 expires on 16 Jul 2025

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.